Logan Coy Related postsAn Open-Label, Multicenter, Phase 1b/2 Study of KRT-232 Combined with Ruxolitinib in Primary Myelofibrosis, Post-PV-MF, or Post-ET-MF with Suboptimal Response to RuxolitinibSeptember 11, 2026Substudy ASPEN-09-03: A Single-arm Phase 2 Study of Evorpacept with Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (ASPEN-09-03), Protocol AT148009September 10, 2026An Open-Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients with Lymphoid Malignancies (the OPAL Study)September 11, 2026 Previous postA Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study of Belantamab as Monotherapy and in Combination with Other Treatments in Multiple MyelomaNext postA Single-arm, Open-label, Phase 2 Study of Subcutaneous Isatuximab via On-Body Delivery System with Weekly Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)